Insmed Inc (Insmed) develops and commercializes therapies for rare diseases. Its portfolio includes ARIKAYCE (amikacin liposome inhalation suspension), an approved treatment for nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). In the US, ARIKAYCE is indicated for patients with refractory MAC lung disease and has received FDA orphan drug and qualified infectious disease product (QIDP) designations for NTM lung disease. ARIKAYCE is also approved for adult MAC-related NTM lung infections by the European Commission and Japan’s Ministry of Health, Labour and Welfare (MHLW), and is marketed as ARIKAYCE liposomal 590 mg nebulizer dispersion (Europe), ARIKAYCE (amikacin liposome inhalation suspension) (US), and ARIKAYCE inhalation 590 mg (Japan).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Insmed is actively engaged in research and development initiatives focused on developing novel gene therapy product candidates to address rare and difficult-to-treat diseases. The company is advancing clinical-stage programs such as INS1201 for Duchenne muscular dystrophy (DMD) and INS1202 for amyotrophic lateral sclerosis (ALS). Additionally, Insmed is leveraging AI and machine learning to enhance drug discovery, development, and commercialization processes. The company is also exploring opportunities in respiratory, immunology, and inflammation therapeutic areas, with a focus on developing first- and best-in-class therapies. The company’s R&D activities are managed through four research laboratories located in New Jersey, New Hampshire, San Diego, and Cambridge, UK. These units collaborate seamlessly across geographies, with individual teams working closely within their own labs and coming together regularly to share insights and refine approaches. A central Research Council evaluates the science and proactively plans the company's IND pipeline. In FY2025, the company spent US$771 million on R&D, which grew 29% YoY. As of December 2025, the company owns or licenses rights to more than 1400 issued patents and pending patent applications globally, including over 400 related to ARIKAYCE. Some of its pipeline products in Phase III include ARIKAYCE for the treatment of MAC Lung Disease, and Brensocatib: DPP1 Inhibitor for the treatment of Non-Cystic Fibrosis Bronchiectasis. Pipeline products in Phase II include Brensocatib to treat Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) and Hidradenitis Suppurativa (HS); Treprostinil Palmitil Inhalation Powder to treat Pulmonary Hypertension associated with Interstitial Lung Diseases (PH-ILD) and Pulmonary Arterial Hypertension (PAH).